Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | PARK7 | Q99497 | 4/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114613 | 0.78 | CASP3 (0.63) | CASP3PARK7CTRCALDH1A1LMNA | |
| SCHEMBL3525847 | 0.76 | CASP3 (0.53) | CASP3PARK7CTRCALDH1A1CUL4A | |
| SCHEMBL18955251 | 0.74 | ALDH1A1 (0.75) | CASP3CTRCALDH1A1CUL4AMAPT | |
| SCHEMBL3027498 | 0.74 | ALDH1A1 (0.64) | CASP3PARK7CTRCALDH1A1LMNA | |
| SCHEMBL2833377 | 0.74 | CASP3 (0.54) | CASP3CTRCALDH1A1LMNA | |
| SCHEMBL2831711 | 0.73 | CASP3 (0.50) | CASP3PARK7CTRCALDH1A1LMNA | |
| SCHEMBL18955128 | 0.73 | ALDH1A1 (0.58) | CASP3PARK7CTRCALDH1A1LMNA | |
| SCHEMBL5119168 | 0.73 | CES1 (0.65) | CASP3CTRCALDH1A1MAPT | |
| SCHEMBL5124354 | 0.73 | CES1 (0.65) | CASP3CTRCALDH1A1MAPT | |
| SCHEMBL2833426 | 0.72 | CASP3 (0.48) | CASP3CTRCALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168101-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2010-07-01 | — | — | US | claimed |
| US-20050043388-A1 | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. | 2005-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043388-A1 | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) | PTPRO, PTPRE, PTPRZ1 | CASP3 4494/4885PARK7 2430/4885CTRC 4670/4885 |
| US-20100168101-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | PTPRO, PTPRE, PTPRZ1 | CASP3 4475/4885PARK7 2437/4885CTRC 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.